Financial Sense Advisors Inc. Decreases Holdings in Amgen Inc. (NASDAQ:AMGN)

Financial Sense Advisors Inc. lowered its position in Amgen Inc. (NASDAQ:AMGN) by 6.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,428 shares of the medical research company’s stock after selling 779 shares during the quarter. Amgen makes up approximately 1.0% of Financial Sense Advisors Inc.’s portfolio, making the stock its 26th biggest position. Financial Sense Advisors Inc.’s holdings in Amgen were worth $2,979,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in AMGN. Capital Performance Advisors LLP purchased a new position in Amgen in the 3rd quarter worth $25,000. Legacy Investment Solutions LLC bought a new position in shares of Amgen during the third quarter valued at about $29,000. Heck Capital Advisors LLC purchased a new position in shares of Amgen in the fourth quarter worth about $36,000. Kennebec Savings Bank bought a new stake in shares of Amgen in the 3rd quarter valued at about $57,000. Finally, PrairieView Partners LLC boosted its holdings in Amgen by 118.3% during the 4th quarter. PrairieView Partners LLC now owns 179 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 97 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

AMGN has been the topic of a number of analyst reports. William Blair reaffirmed an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. Jefferies Financial Group reiterated a “buy” rating and set a $380.00 price target on shares of Amgen in a report on Tuesday, November 12th. Truist Financial cut their price target on shares of Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a report on Wednesday, January 8th. Bank of America upped their price objective on shares of Amgen from $256.00 to $275.00 and gave the company an “underperform” rating in a research note on Thursday, February 6th. Finally, Wells Fargo & Company cut their target price on Amgen from $335.00 to $280.00 and set an “equal weight” rating on the stock in a research note on Friday, January 10th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $314.09.

Insiders Place Their Bets

In related news, EVP Jonathan P. Graham sold 25,045 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the sale, the executive vice president now owns 28,987 shares of the company’s stock, valued at $8,496,669.44. This trade represents a 46.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Murdo Gordon sold 8,771 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the completion of the transaction, the executive vice president now owns 44,186 shares of the company’s stock, valued at approximately $13,025,590.94. The trade was a 16.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,405 shares of company stock valued at $10,410,596. 0.69% of the stock is currently owned by corporate insiders.

Amgen Stock Up 0.5 %

Shares of Amgen stock opened at $294.27 on Thursday. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The firm has a market cap of $158.18 billion, a price-to-earnings ratio of 38.98, a PEG ratio of 2.53 and a beta of 0.56. The company has a 50-day moving average of $275.15 and a 200 day moving average of $300.77. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, sell-side analysts anticipate that Amgen Inc. will post 20.6 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a dividend of $2.38 per share. This is a boost from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a yield of 3.24%. Amgen’s payout ratio is presently 126.09%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.